Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSareum Regulatory News (SAR)

Share Price Information for Sareum (SAR)

Share Price is delayed by 15 minutes
Get Live Data
22.50    1.00 (4.65%)
Bid:
22.00
Ask:
23.00
Spread: 1.00 (4.545%)
Market Cap: £31.18m
SAR Live PriceLast checked at - London Stock Exchange

Intraday Sareum Share Chart

Corporate update

19 Jun 2008 07:00

RNS Number : 0476X
Sareum Holdings PLC
19 June 2008
 



19 June 2008

SAREUM HOLDINGS PLC

("Sareum" or "the Company")

Corporate Update

Sareum Holdings plc (AIM: SAR), the specialist structure-based drug discovery business, announced on 2 May 2008, that the Board was undertaking a strategic review to consider how best to take the business forward and create value for shareholders. 

 

On 14 May, the Company announced that as part of the strategic review, the board had implemented a staff restructuring process to reduce its cost base by approximately one third and prepare itself for any potential acquisition or re-financing whilst the future business strategy is under consideration. The restructuring programme has been successfully completed and the Sareum board will continue to review the Company's cost base diligently. In addition, the Company is making progress on a number of fronts and these are described below.

Following announcement of the review on 2 May, Sareum has received expressions of interest in parts or all of its business, particularly its valuable drug discovery programmes, and has received interest in and possible offers to partner, fund, acquire or invest in certain of its programmes or assets. Any transaction resulting from these discussions would lead to an injection of cash into the Company. Initial due diligence is currently being undertaken in respect of several of these discussions. These discussions are at various stages and there is no certainty that any one of them will lead to an offer being made for the Company or any of its assets. The Sareum board continues to actively progress discussions and further announcements will be made as appropriate. 

The Board has concluded, as a result of this review, that the Company should undertake a strategic transaction and it will need to effect a fundraising to enable it to complete such a transaction. In order to facilitate this, the Company will shortly be sending a notice to shareholders convening a general meeting at which shareholders will be asked to give the directors authority to issue further shares for cash. Should the Board decide within a short timescale that strategic transaction is not achievable, the Board will take a decision as to the future of the Company in its present form, as the Company would not be able to continue operations without a significant fundraising.

- Ends-

For further information please contact

Sareum Holdings plc

01223 497700

Tim Mitchell, Chief Executive Officer

 

Buchanan Communications

020 7466 5000

Tim Anderson, Mary-Jane Johnson 

 

Grant Thornton Corporate Finance

020 7383 5100

Philip Secrett, Colin Aaronson

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCQVLFFVQBZBBD
Date   Source Headline
17th Jun 20214:35 pmRNSPrice Monitoring Extension
17th Jun 202111:05 amRNSSecond Price Monitoring Extn
17th Jun 202111:00 amRNSPrice Monitoring Extension
16th Jun 20212:05 pmRNSSecond Price Monitoring Extn
16th Jun 20212:00 pmRNSPrice Monitoring Extension
16th Jun 20219:06 amRNSSecond Price Monitoring Extn
16th Jun 20219:00 amRNSPrice Monitoring Extension
15th Jun 202111:19 amRNSSubscription to raise £1,470,000
14th Jun 20214:40 pmRNSSecond Price Monitoring Extn
14th Jun 20214:35 pmRNSPrice Monitoring Extension
9th Jun 20219:05 amRNSSecond Price Monitoring Extn
9th Jun 20219:00 amRNSPrice Monitoring Extension
1st Jun 20212:05 pmRNSSecond Price Monitoring Extn
1st Jun 20212:00 pmRNSPrice Monitoring Extension
1st Jun 202111:06 amRNSSecond Price Monitoring Extn
1st Jun 202111:00 amRNSPrice Monitoring Extension
1st Jun 20217:00 amRNSSubscription to raise £900,000
25th May 20219:05 amRNSSecond Price Monitoring Extn
25th May 20219:00 amRNSPrice Monitoring Extension
25th May 20217:00 amRNSTrading Statement
17th May 20214:36 pmRNSPrice Monitoring Extension
13th May 20217:00 amRNSExercise of Options and Total Voting Rights
5th May 20211:15 pmEQSEdison Investment Research Limited: Sareum Holdings (SAR): Treading the TYK2 trail
5th May 20217:00 amEQSSareum Holdings (SAR): Treading the TYK2 trail
23rd Apr 20217:00 amRNSHalf-year Report
25th Mar 20212:07 pmRNSResearch Update
25th Mar 20217:00 amRNSInterim Results Extension
16th Feb 20217:00 amRNSSareum Notes New UK Government Covid-19 Initiative
1st Feb 20217:00 amRNSSareum to Present at the LSX World Congress 2021
26th Jan 20217:00 amRNSSareum to Participate in the Edison Open House
11th Jan 202111:06 amRNSSecond Price Monitoring Extn
11th Jan 202111:01 amRNSPrice Monitoring Extension
8th Jan 20213:54 pmRNSUpdate re: FLT3+Aurora Kinase Inhibitor Programme
7th Jan 20217:00 amRNSUS Patent Grant for TYK2/JAK1 Anticancer Candidate
22nd Dec 202011:05 amRNSSecond Price Monitoring Extn
22nd Dec 202011:00 amRNSPrice Monitoring Extension
15th Dec 202012:59 pmRNSResult of AGM
15th Dec 20207:00 amRNSAGM Statement
14th Dec 20207:00 amRNSNature article highlights role of TYK2 in Covid-19
3rd Dec 20207:00 amRNSCovid-19 Research Grant Confirmed
19th Nov 20207:00 amRNSNotice of AGM
12th Nov 202012:13 pmRNSUpdate on SRA737 Licensing Agreement
27th Oct 202011:00 amRNSNotification of Grant Award for Covid-19 Research
26th Oct 202011:05 amRNSSecond Price Monitoring Extn
26th Oct 202011:00 amRNSPrice Monitoring Extension
20th Oct 20201:00 pmRNSExercise of Share Options and Director Dealings
13th Oct 20207:01 amRNSFull Year Results Investor Presentation
13th Oct 20207:00 amRNSFinal Results
12th Oct 20204:41 pmRNSSecond Price Monitoring Extn
12th Oct 20204:36 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.